Para IV Winners and Losers - September 2018
This month’s Para IV developments suggest that there is likely to be benefit to Teva Pharmaceutical Sp Adr (TEVA US) on Vesicare, Soolantra and...
588 Views
Para IV Winners and Losers - August 2018
This month’s Para IV developments suggest that there is likely to be benefit to Mylan Nv (MYL US) for Minivelle, Teva Pharmaceutical Sp Adr (TEVA...
417 Views
Para IV Winners & Losers - May 2018
This month’s Para IV developments suggest that there is likely to be benefit to Amneal Pharmaceuticals Inc (AMRX US) on Lialda, BioQ pharma for...
215 Views
Global Equity Strategy: Overweight EM
Big-picture technicals offer a compelling outlook for equities -- in the long-run. Despite arguably stretched trends, especially in the U.S. and...
839 Views
Global Equity Strategy: Sector by Sector Overview
Today’s report is international in title, global in coverage. Inside, after reviewing trends in EM, Europe, and Japan--EM looks great, by the way,...
334 Views